COMBINED ORAL CONTRACEPTIVE (ETHINYLESTRADIOL/ LEVONORGESTREL) ALLEVIATES LIPID AND LACTATE ALTERATIONS IN PLASMODIUM BERGHEI-INFECTED MICE

Simple item page
dc.contributor.authorAbdulkareem, A.O
dc.contributor.authorBabamale, O.A
dc.contributor.authorAbe, E.O
dc.contributor.authorOlatunji, L.A
dc.contributor.authorUgbomoiko, U.S
dc.date.accessioned2023-04-03T13:16:31Z
dc.date.available2023-04-03T13:16:31Z
dc.date.issued2022-04-08
dc.description.abstractDespite the common use of combined oral contraceptive (COC) as a childbirth control pill, there is no sufficient information on the effect of COC in malaria. Hence, we aimed at investigating the effect of COC on parasite growth and the associated risk of metabolic disorder in Plasmodium berghei-infected mice. Twenty female mice were randomly allotted into four groups (n= 5/group): uninfected, infected (inoculated with P. berghei), COC (1.0 μg ethinylestradiol and 5.0 μg levonorgestrel, p.o/day, without infection) and infected + COC. Percentage parasitaemia was recorded weekly. At the end of 21-day exposure, the mice were sacrificed, while blood and liver were collected for biochemical analyses. Our data showed progressive increase in parasitaemia in P. berghei-infected mice. Our findings also revealed that P. berghei infection did not affect serum levels of high-density lipoprotein cholesterol, low density lipoprotein cholesterol and total cholesterol (TC). It, however, elevated serum malondialdehyde (MDA), serum and liver triglycerides and liver TC. Elevations of serum and liver free fatty acid and lactate were also observed in P. berghei-infected mice. However, COC treatment lowered MDA level and attenuated lipid and lactate alterations in P. berghei infection. This study, therefore, suggests that COC possesses anti-plasmodial potential to mitigate malaria-associated metabolic disturbances. Further animal and human studies are necessary to validate our findings.en_US
dc.identifier.urihttps://uilspace.unilorin.edu.ng/handle/20.500.12484/8976
dc.publisherAssiut University, Egypten_US
dc.subjectPlasmodium bergheien_US
dc.subjectmalariaen_US
dc.subjectCOCen_US
dc.subjectmetabolicen_US
dc.subjectlipiden_US
dc.titleCOMBINED ORAL CONTRACEPTIVE (ETHINYLESTRADIOL/ LEVONORGESTREL) ALLEVIATES LIPID AND LACTATE ALTERATIONS IN PLASMODIUM BERGHEI-INFECTED MICEen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Abdulkareem et al., 2022 (BFSA_Volume 45_Issue 2_Pages 925-934).pdf
Size:
785.49 KB
Format:
Adobe Portable Document Format
Description:
Research article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections